Monitored issues related to drug pricing; S. 3787, The Developing and Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2018.
Issues related to antimicrobials; issues related to the reauthorization of PAHPA, including S. 2852 / H.R. 6378, Pandemic All Hazards Preparedness Act of 2018.
Monitored H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act and Continuing Appropriations Act. Monitored H.R. 695, Further Additional Continuing Appropriations Act.
Monitored issues related to NAFTA.
Duration: January 22, 2015
to
December 31, 2018
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Veterans
Spending: about $780,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Food & Drug Administration (FDA), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stacey Hughes U.S. Senate Budget Committee, Deputy Staff Director
Office of the Asst. Maj. Leader (Sen. Nickles), Policy Adv.
Office of the Asst. Min. Leader (Sen. Nickles), Policy Adv.
Senate Spec. Cmte on Aging (Sen Cohen), Prof. Staff Member
U.S. Senator Connie Mack, Leg. Asst / Scheduler
Emily Porter Ofce of Spkr(Rep.Boehner),Asst to Spkr for Policy
Ofce of Min. Leader (Rep.Boehner), Policy Adv.
Ofce of the Maj. Leader (Rep. Boehner),Policy Adv
Cmte on Ed & the Wrkfrc (Rep.Boehner),Coalitions Dir. for Ed
Rep. Trent Franks, Sr. Leg. Asst.
Rep. Tom Tancredo, Leg. Asst.
Mary Beth Savary Taylor Joint Economic Committee, General Counsel
U.S. Senator Connie Mack, Legislative Assistant
Rachel Jones Hensler U.S. Senate Budget Committee, Tax Policy Dir.; Office of U.S. Senator Fred Thompson, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Correspondent
Stephanie Badger n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
THE NICKLES GROUP, LLC terminated an engagement in which they represented Merck & Co. Inc. on Jan. 18, 2019.
Original Filing: 301010457.xml
Lobbying Issues
Monitored issues related to drug pricing; S. 3787, The Developing and Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; issues related to the reauthorization of PAHPA, including S. 2852 / H.R. 6378, Pandemic All Hazards Preparedness Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act and Continuing Appropriations Act. Monitored H.R. 695, Further Additional Continuing Appropriations Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to NAFTA.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994497.xml
Lobbying Issues
Issues related to drug pricing and the Medicare Part D program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; issues related to the reauthorization of PAHPA, including S. 2852 / H.R. 6378, Pandemic All Hazards Preparedness Act of 2018; monitored issues related to H.R. 5554, The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (ADUFA) and (AGDUFA). Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on July 20, 2018.
Original Filing: 300976329.xml
Lobbying Issues
Issues related to drug pricing and the Medicare Part D program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; issues related to the reauthorization of PAHPA; monitored issues related to the Right to Try Act of 2018; H.R. 5599, Animal Health and Innovation Act; H.R. 5554, The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (ADUFA) and (AGDUFA). Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on April 20, 2018.
Original Filing: 300954412.xml
Lobbying Issues
Issues related to drug pricing and the Medicare Part D program; monitored issues related to the Medicare outpatient payment system.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; issues related to the reauthorization of PAHPA; Monitored issues related to the Right to Try Act of 2018; S. 1827; Monitored issues related to Keep Kids Insurance Dependable and Secure Act of 2017; Issues related to the Animal Drug User Fee (ADUFA) and Animal Generic Drug User Fee Act (AGDUFA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R 1892 The Bipartisan Budget Act of 2018 and issues related to Medicare drug pricing; H.R. 1625, Monitored the Consolidated Appropriations Act 2018 and issues related to Medicare drug pricing.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934789.xml
Lobbying Issues
Issues related to antimicrobials; issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1, The Tax Cut and Jobs Act, as it relates to corporate tax reform and the taxation of U.S. multinational companies.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H. Con. Res. 71 and issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on Oct. 19, 2017.
Original Filing: 300909095.xml
Lobbying Issues
Issues related to antimicrobials; issues related to Part B drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; monitored H.R. 1628, The American Health Care Act of 2017; S. 934 and H.R. 2430, The FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to tax reform and the taxation of U.S. multi-nationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on July 20, 2017.
Original Filing: 300894572.xml
Lobbying Issues
Issues related to antimicrobials; issues related to Part B drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; monitored H.R. 1628, The American Health Care Act of 2017; S. 934 and H.R. 2430, The FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to tax reform and the taxation of U.S. multi-nationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on April 20, 2017.
Original Filing: 300873835.xml
Lobbying Issues
Issues related to antimicrobials; issue related to Medicare Part B demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to antimicrobials; monitored H.R. 1628, The American Health Care Act of 2017; issues related to prescription drug user fees.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to tax reform and the taxation of U.S. multi-nationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. Con. Res. 3, FY '17 Budget Resolution.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856027.xml
Lobbying Issues
Issues related to antimicrobials, issues related to Medicare Part B demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.34, The 21st Century Cures Act and issues related to antimicrobials; issues related to shingles and education on HPV-related cancers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and the taxation of U.S. multi-nationals. Monitor issues related to the Treasury Department's proposed Sect. 385 regulations.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on Oct. 20, 2016.
Original Filing: 300838348.xml
Lobbying Issues
Issues related to antimicrobials, issues related to Medicare Part B demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6, The 21st Century Cures Act and issues related to antimicrobials; issues related to the Innovation Initiative; issues related to shingles and education on HPV-related cancers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and the taxation of U.S. multi-nationals. Monitor issues related to the Treasury Department's proposed Sect. 385 regulations.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on July 20, 2016.
Original Filing: 300817801.xml
Lobbying Issues
Issues related to antimicrobials, issues related to Medicare Part B demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6, The 21st Century Cures Act and issues related to antimicrobials; issues related to the Innovation Initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and the taxation of U.S. multi-nationals. Monitor issues related to the Treasury Department's proposed Sect. 385 regulations. Monitor S. 2328, PROMESA.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $45,000. The report was filed on April 20, 2016.
Original Filing: 300801156.xml
Lobbying Issues
Issues related to antimicrobials, issues related to Medicare Part B demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6, The 21st Century Cures Act and issues related to antimicrobials; issues related to the Innovation Initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and the taxation of U.S. multi-nationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to access to drugs for Hepatitis C.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $60,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781952.xml
Lobbying Issues
Issues related to antimicrobials.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6, The 21st Century Cures Act and issues related to antimicrobials; issues related to the Innovation Initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and the taxation of U.S. multi-nationals. S. 1946, the Tax Relief Extension Act of 2015; H.R. 34, the Tax Increase Prevention and Real Estate Investment Act of 2015; H.R. 2029, Consolidated Appropriations Act, 2016, as they relate to the R&D tax credit, the CFC look-through rules, and bonus depreciation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300759449.xml
Lobbying Issues
Issues related to antimicrobials and H.R. 512, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6, The 21st Century Cures Act and issues related to antimicrobials; issues related to the Innovation Initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and the taxation of U.S. multi-nationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300744123.xml
Lobbying Issues
Issues related to antimicrobials and H.R. 512, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015; issues related to Part D reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6, The 21st Century Cures Act and issues related to antimicrobials; issues related to the Innovation Initiative.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, THE NICKLES GROUP, LLC lobbied for Merck & Co. Inc. , earning $60,000. The report was filed on April 20, 2015.
Original Filing: 300725813.xml
Lobbying Issues
Issues related to antimicrobials and H.R. 512, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...